ReviewThe Lancet. Rheumatology2021
Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective.
Review in The Lancet. Rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.Annals of the rheumatic diseases · 2024Pooled it
- The spectrum of giant cell arteritis through a rheumatology lens.Eye (London, England) · 2024Review
- Review
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.Rheumatic diseases clinics of North America · 2023Review
- COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study.Journal of autoimmunity · 2022Observational
- Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica.RMD open · 2022Article
- COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.Clinical rheumatology · 2022Review
- Article
- Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica.Arthritis research & therapy · 2022Article
- An update on the clinical approach to giant cell arteritis.Clinical medicine (London, England) · 2022Article
- [Efficacy and safety of SARS-CoV-2 vaccine in patients with giant cell arteritis].Medicina clinica · 2022Article
- Efficacy and safety of SARS-CoV-2 vaccine in patients with giant cell arteritis.Medicina clinica (English ed.) · 2022Article
- Role of temporal artery resection in Horton's arteritis (Review).Experimental and therapeutic medicine · 2021Review
- Giant cell arteritis during COVID-19 pandemic.Arquivos brasileiros de oftalmologia · 2021Article
- Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis.Clinical & translational immunology · 2021Article
Corrections and comments
- Erratum issuedCorrection to2021
Authors and funding
10 authors at 9 institutions in 5 countries.
Funding
Abstract
Giant cell arteritis, a common primary systemic vasculitis affecting older people, presents acutely as a medical emergency and requires rapid specialist assessment and treatment to prevent irreversible vision loss. Disruption of the health-care system caused by the COVID-19 pandemic exposed weak points in clinical pathways for diagnosis and treatment of giant cell arteritis, but has also permitted innovative solutions. The essential roles played by all professionals, including general practitioners and surgeons, in treating these patients have become evident. Patients must also be involved in the reshaping of clinical services. As an international group of authors involved in the care of patients with giant cell arteritis, we reflect in this Viewpoint on rapid service adaptations during the first peak of COVID-19, evaluate challenges, and consider implications for the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.